MET
60
2
TXT
66
-3
SYY
49
2
WHR
70
2
NKE
30
2
JBHT
68
3
FIS
55
5
AZO
52
-4
KR
52
2
WEC
53
8
GME
65
6
K
59
6
MSI
81
9
NTAP
64
3
GT
67
3
CCI
38
2
ED
46
3
WMT
63
3
SE
50
-5
IBM
53
2
MET
60
2
TXT
66
-3
SYY
49
2
WHR
70
2
NKE
30
2
JBHT
68
3
FIS
55
5
AZO
52
-4
KR
52
2
WEC
53
8
GME
65
6
K
59
6
MSI
81
9
NTAP
64
3
GT
67
3
CCI
38
2
ED
46
3
WMT
63
3
SE
50
-5
IBM
53
2
Financhill
Back

BioCryst Pharmaceuticals Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Sell
33

BCRX
BioCryst Pharmaceuticals

Last Price:
7.78
Seasonality Move:
8.68%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

BioCryst Pharmaceuticals Price Quote

$7.78

BioCryst Pharmaceuticals Key Stats

Sell
33
BioCryst Pharmaceuticals (BCRX) is a Sell
Day range:
$7.52 - $7.84
52-week range:
$4.03 - $8.88
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.87
P/B ratio:
0%
Volume:
1.6M
Avg. volume:
2.1M
1-year change:
42.23%
Market cap:
$1.6B
Revenue:
$331.4M
EPS:
$-0.61

How Much Does BioCryst Pharmaceuticals Make?

Is BioCryst Pharmaceuticals Growing As A Company?

BioCryst Pharmaceuticals Stock Price Performance

What Is BioCryst Pharmaceuticals 52-Week High & Low?

BioCryst Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy BioCryst Pharmaceuticals?

Is BioCryst Pharmaceuticals Cash Flow Positive?

  • What Is BCRX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$55.7M
  • What Is BioCryst Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$4.9M
  • What Is BioCryst Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $6.3M

BioCryst Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    BCRX return on invested capital is -34.87%
  • What Is BioCryst Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -25.05%
  • What Is BCRX Return On Equity?
    ROE is a measure of profitability and is 0%

BioCryst Pharmaceuticals Earnings Date & Stock Price

BioCryst Pharmaceuticals Competitors

BioCryst Pharmaceuticals Dividend Yield

BioCryst Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -21.74%
Revenue: 34.98% 2.71%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 14.64
Upside from Last Price: 88.13%

Major Shareholders

  • How many BCRX shares are owned by institutional investors?
    244.8M BCRX shares are owned by institutional investors
  • How many BCRX shares are owned by insiders?
    6.4M BCRX shares are owned by insiders